Several other research analysts also recently commented on PRQR. Royal Bank of Canada reaffirmed a “buy” rating and issued a $27.00 price objective on shares of ProQR Therapeutics in a report on Sunday, August 11th. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a report on Wednesday, August 14th. ValuEngine downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Chardan Capital set a $25.00 price objective on shares of ProQR Therapeutics and gave the stock a “buy” rating in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $27.00.
Shares of PRQR stock traded up $0.06 during trading hours on Wednesday, hitting $7.01. 1,863 shares of the company were exchanged, compared to its average volume of 178,739. The firm has a fifty day simple moving average of $8.08 and a 200 day simple moving average of $10.99. The stock has a market capitalization of $270.54 million, a price-to-earnings ratio of -5.50 and a beta of 0.18. ProQR Therapeutics has a 52-week low of $6.73 and a 52-week high of $24.00. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.16.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRQR. Geode Capital Management LLC boosted its holdings in ProQR Therapeutics by 14.1% in the 4th quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 2,375 shares during the period. Deutsche Bank AG bought a new position in ProQR Therapeutics in the 4th quarter worth approximately $137,000. Altrinsic Global Advisors LLC boosted its holdings in ProQR Therapeutics by 9.8% in the 1st quarter. Altrinsic Global Advisors LLC now owns 199,060 shares of the biopharmaceutical company’s stock worth $2,761,000 after buying an additional 17,700 shares during the period. Clearbridge Investments LLC boosted its holdings in ProQR Therapeutics by 0.6% in the 1st quarter. Clearbridge Investments LLC now owns 495,227 shares of the biopharmaceutical company’s stock worth $6,869,000 after buying an additional 2,939 shares during the period. Finally, Swiss National Bank boosted its holdings in ProQR Therapeutics by 5.4% in the 2nd quarter. Swiss National Bank now owns 49,100 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 2,500 shares during the period. 60.79% of the stock is owned by institutional investors.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.